United Therapeutics Corporation
UTHR
$479.19
-$0.76-0.16%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.11% | 0.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.11% | 0.53% | |||
| Cost of Revenue | 15.18% | -5.30% | |||
| Gross Profit | -1.74% | 1.30% | |||
| SG&A Expenses | -14.45% | 24.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.51% | 5.47% | |||
| Operating Income | 6.80% | -4.78% | |||
| Income Before Tax | 7.25% | -3.57% | |||
| Income Tax Expenses | 0.40% | -2.37% | |||
| Earnings from Continuing Operations | 9.43% | -3.94% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.43% | -3.94% | |||
| EBIT | 6.80% | -4.78% | |||
| EBITDA | 6.64% | -4.22% | |||
| EPS Basic | 12.68% | -4.37% | |||
| Normalized Basic EPS | 8.11% | -4.25% | |||
| EPS Diluted | 11.70% | -3.32% | |||
| Normalized Diluted EPS | 7.22% | -3.23% | |||
| Average Basic Shares Outstanding | -2.88% | 0.45% | |||
| Average Diluted Shares Outstanding | -2.07% | -0.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||